Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Prog Retin Eye Res. 2021 Mar 26;85:100967. doi: 10.1016/j.preteyeres.2021.100967

Figure 13.

Figure 13.

The potential of MSC-derived EVs as cell-free alternatives to MSCs for the treatment of disease.

MSCs produce EVs which contain a large number of therapeutic molecules including RNAs, proteins and mitochondria. MSC-EVs have been shown to exert therapeutic benefits in a wide range of animal models of human diseases.